Ragoonanan, Dristhi and Khazal, Sajad J. and Abdel-Azim, Hisham and McCall, David and Cuglievan, Branko and Tambaro, Francesco Paolo and Ahmad, Ali Haider and Rowan, Courtney M. and Gutierrez, Cristina and Schadler, Keri and Li, Shulin and Di Nardo, Matteo and Chi, Linda and Gulbis, Alison M. and Shoberu, Basirat and Mireles, Maria E. and McArthur, Jennifer and Kapoor, Neena and Miller, Jeffrey and Fitzgerald, Julie C. and Tewari, Priti and Petropoulos, Demetrios and Gill, Jonathan B. and Duncun, Christine N. and Lehmann, Leslie E. and Hingorani, Sangeeta and Angelo, Joseph R. and Swinford, Rita D. and Steiner, Marie E. and Hernandez Tejada, Fiorela N. and Martin, Paul L. and Auletta, Jeffery and Choi, Sung Won and Bajwa, Rajinder and Dailey Garnes, Natalie and Kebriaei, Partow and Rezvani, Katayoun and Wierda, William G. and Neelapu, Sattva S. and Shpall, Elizabeth J. and Corbacioglu, Selim and Mahadeo, Kris M. (2021) Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 18 (7). pp. 435-453. ISSN 1759-4774, 1759-4782
Full text not available from this repository. (Request a copy)Abstract
In this Consensus Statement, members from five working groups or societies provide updated comprehensive recommendations to manage toxicities from cancer immunotherapies in children, adolescents and young adults. In their recommendations, they advocate for the adoption of age-based and discipline-specific management criteria, and call for an increased inclusion of young patients with cancer in clinical trials. Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | T-CELL THERAPY; NATURAL-KILLER-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; VERSUS-HOST-DISEASE; CHECKPOINT INHIBITOR THERAPY; ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; SOLID-ORGAN TRANSPLANT; OPEN-LABEL; METASTATIC MELANOMA |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Petra Gürster |
| Date Deposited: | 11 Jan 2023 09:06 |
| Last Modified: | 11 Jan 2023 09:06 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48198 |
Actions (login required)
 |
View Item |
